IL143386A0 - Pharmaceutical dosage form comprising a h+, k+ -atpase inhibitor and gastric antisecretory prostaglandin analogue compound - Google Patents

Pharmaceutical dosage form comprising a h+, k+ -atpase inhibitor and gastric antisecretory prostaglandin analogue compound

Info

Publication number
IL143386A0
IL143386A0 IL14338699A IL14338699A IL143386A0 IL 143386 A0 IL143386 A0 IL 143386A0 IL 14338699 A IL14338699 A IL 14338699A IL 14338699 A IL14338699 A IL 14338699A IL 143386 A0 IL143386 A0 IL 143386A0
Authority
IL
Israel
Prior art keywords
dosage form
pharmaceutical dosage
atpase inhibitor
prostaglandin analogue
analogue compound
Prior art date
Application number
IL14338699A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL143386A0 publication Critical patent/IL143386A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL14338699A 1998-12-14 1999-12-10 Pharmaceutical dosage form comprising a h+, k+ -atpase inhibitor and gastric antisecretory prostaglandin analogue compound IL143386A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9804314A SE9804314D0 (sv) 1998-12-14 1998-12-14 New pharmaceutical formulation
PCT/SE1999/002315 WO2000035448A1 (fr) 1998-12-14 1999-12-10 Nouvelle formulation pharmaceutique

Publications (1)

Publication Number Publication Date
IL143386A0 true IL143386A0 (en) 2002-11-10

Family

ID=20413648

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14338699A IL143386A0 (en) 1998-12-14 1999-12-10 Pharmaceutical dosage form comprising a h+, k+ -atpase inhibitor and gastric antisecretory prostaglandin analogue compound

Country Status (14)

Country Link
EP (1) EP1150677A1 (fr)
JP (1) JP2002532425A (fr)
KR (1) KR20010093822A (fr)
CN (1) CN1334731A (fr)
AU (1) AU776079B2 (fr)
BR (1) BR9916224A (fr)
CA (1) CA2352613A1 (fr)
HK (1) HK1041224A1 (fr)
IL (1) IL143386A0 (fr)
NO (1) NO20012915L (fr)
NZ (1) NZ511999A (fr)
SE (1) SE9804314D0 (fr)
WO (1) WO2000035448A1 (fr)
ZA (1) ZA200104273B (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US7815937B2 (en) * 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US8268333B2 (en) 2001-04-24 2012-09-18 Lintec Corporation Orally administered agent and an orally administered agent/supporting substrate complex
ITMI20020515A1 (it) * 2002-03-12 2003-09-12 Jagotec Ag Sistema per il rilasco controllato di uno o piu' principi attivi
WO2004082665A1 (fr) * 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Composition à libération contrôlée
ZA200508932B (en) * 2003-06-06 2007-03-28 Takeda Pharmaceutical Solid pharmaceutical preparation
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2005289867A (ja) * 2004-03-31 2005-10-20 Lintec Corp 経口投与剤
CN1311824C (zh) * 2004-04-21 2007-04-25 常州市第四制药厂有限公司 奥美拉唑肠溶微粒制剂及制备方法
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
RU2468800C2 (ru) * 2005-04-12 2012-12-10 Сукампо Аг Комбинированное применение производного простагландина и ингибитора протонового насоса для лечения желудочно-кишечных заболеваний
EP1987820A1 (fr) * 2007-05-04 2008-11-05 Christian Fiala, Ph. D. Misoprostole à libération lente pour applications obstétriques et/ou gynécologiques
CN102078615A (zh) * 2011-01-21 2011-06-01 北京华禧联合科技发展有限公司 质子泵抑制剂和胃黏膜保护剂组合物
WO2016010741A1 (fr) * 2014-07-17 2016-01-21 Dow Global Technologies Llc Dispersion et film d'éthylcellulose
US10653777B2 (en) 2015-02-10 2020-05-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10517950B1 (en) 2015-02-10 2019-12-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11110173B2 (en) 2015-02-10 2021-09-07 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US11602563B2 (en) 2015-02-10 2023-03-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695430B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11738085B2 (en) 2015-02-10 2023-08-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821181B2 (en) 2015-02-10 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758618B2 (en) 2015-02-10 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11045549B2 (en) 2015-02-10 2021-06-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11607456B2 (en) 2015-02-10 2023-03-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10722583B2 (en) 2015-02-10 2020-07-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729773B2 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512692B2 (en) 2015-02-10 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933137B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10702602B2 (en) 2015-02-10 2020-07-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780165B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013805B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10532101B1 (en) 2015-02-10 2020-01-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729774B1 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695429B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933136B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780166B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10537642B1 (en) 2015-02-10 2020-01-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013806B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10799588B2 (en) 2015-02-10 2020-10-13 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
EP3288556A4 (fr) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Compositions à désintégration par voie orale
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US11806354B2 (en) 2017-01-04 2023-11-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583144B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583088B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11207327B2 (en) 2017-01-04 2021-12-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729696B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10561664B1 (en) 2017-01-04 2020-02-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10940153B2 (en) 2017-01-04 2021-03-09 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617755B2 (en) 2017-01-04 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
JP6870867B2 (ja) 2017-01-04 2021-05-12 アクスサム セラピューティクス インコーポレイテッド メロキシカムを含有する医薬組成物
US10471014B2 (en) 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11801250B2 (en) 2017-01-04 2023-10-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433078B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821182B2 (en) 2017-06-29 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433079B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729697B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11471465B2 (en) 2017-01-04 2022-10-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11266657B2 (en) 2017-01-04 2022-03-08 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10894053B2 (en) 2017-01-04 2021-01-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10905693B2 (en) 2017-01-04 2021-02-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10918722B2 (en) 2017-06-29 2021-02-16 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11759522B2 (en) 2017-06-29 2023-09-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11510927B2 (en) 2017-06-29 2022-11-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617756B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617791B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10987358B2 (en) 2017-06-29 2021-04-27 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512693B2 (en) 2017-06-29 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11185550B2 (en) 2017-06-29 2021-11-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688185B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758617B2 (en) 2017-06-29 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11865117B2 (en) 2017-06-29 2024-01-09 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US11219626B2 (en) 2017-06-29 2022-01-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688102B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Combination treatment for migraine and other pain

Also Published As

Publication number Publication date
CN1334731A (zh) 2002-02-06
EP1150677A1 (fr) 2001-11-07
AU2018600A (en) 2000-07-03
NZ511999A (en) 2002-10-25
CA2352613A1 (fr) 2000-06-22
WO2000035448A1 (fr) 2000-06-22
JP2002532425A (ja) 2002-10-02
BR9916224A (pt) 2001-09-04
ZA200104273B (en) 2002-08-26
KR20010093822A (ko) 2001-10-29
AU776079B2 (en) 2004-08-26
NO20012915L (no) 2001-08-13
HK1041224A1 (zh) 2002-07-05
SE9804314D0 (sv) 1998-12-14
NO20012915D0 (no) 2001-06-13

Similar Documents

Publication Publication Date Title
IL143386A0 (en) Pharmaceutical dosage form comprising a h+, k+ -atpase inhibitor and gastric antisecretory prostaglandin analogue compound
AU3977099A (en) Controlled release oral dosage form
AU1998200A (en) Multiparticulate oral dosage forms
GB9801363D0 (en) Novel dosage form
HK1155649A1 (en) Dosage unit comprising a prostaglandin analog for treating constipation
IL191582A0 (en) Polymorph of a pharmaceutical
GB2347702B (en) Packing system for boreholes
ZA964374B (en) A pharmaceutical compositions for inhibiting the growth of cancers.
IL138192A0 (en) Controlled release oral dosage forms
IL161143A0 (en) A flash-melt pharmaceutical oral dosage composition
PL345332A1 (en) A substituted triazolo-pyridazine derivative, pharmaceutical compositions made therefrom
AU2199500A (en) Gastric retention dosage form having multiple layers
IL145632A0 (en) Pharmaceutical compounds
AU2003257102A1 (en) Pharmaceutical dosage form comprising a sulfite compound
HK1048112B (zh) 3-乙烯基-頭孢化合物的製備方法
IL144767A0 (en) Method for producing film-type dosage forms
GB2373499B (en) Pharmaceutical compounds
AU7773900A (en) Novel c13-substituted estra-1,3,5(10)-triene-3-yl-sulfamates, a method for producing the same and pharmaceutical compositions containing these compounds
HUP0203655A3 (en) Unsaturated 14,15-cyclopropane-androstanes, a method for their production and pharmaceutical compositions containing these compounds
PL354872A1 (en) Oral dosage form comprising a salt of morphine or a morphine derivative
IL131317A0 (en) A binder for pharmaceutical compositions
HUP0100190A3 (en) The use of a phenylcarbamide derivative (pencycuron) for inhibiting the late beet rooting
AU1717392A (en) Brick tie
ZA966529B (en) A pharmaceutical composition for inhibiting the growth of cancers.
GB9925069D0 (en) Oral dosage form